Table 3 Immune response following vaccination stratified according to age irrespective of number of doses
|  | All patients (number = 291) | RA on MTX (number = 50) | RA on anti-TNF monotherapy (number = 38) | RA on anti-TNF + MTX (number = 53) | RA on abatacept (number = 5) | RA on rituximab (number = 10) | RA on tocilizumab (number = 2) | SpA on anti-TNF monotherapy (number = 41) | SpA on anti-TNF + MTX (number = 51) | SpA on NSAIDs/ analgesics controls (umber = 41) |
|---|---|---|---|---|---|---|---|---|---|---|
≥60 years | ||||||||||
Patients (number) | 149 | 36 | 27 | 35 | 2 | 7 | 1 | 10 | 16 | 15 |
GMT prevaccination mean (95% CI) | 8.1 (7.2 to 9.2) | 8.6 (6.5 to 11.3) | 9.5 (6.5 to 13.8) | 6.3 (5.3 to 7.6) | ---- | 6.1 (3.8 to 9.9) | --- | 8.7 (5.2 to 14.5) | 12 (8 to 17.6) | 7.2 (5.3 to 10) |
GMT postvaccination mean (95% CI) | 30 (24.3 to 37) | 26.2 (17.2 to 39.9) | 42.1 (22.7 to 78.1) | 24.9 (16.8 to 36.8) | ---- | 12.2 (5.5-27.2) | ---- | 92 (46 to 184) | 19 (11.7 to 31.4) | 42 (18.6 to 95) |
Geometric mean fold increase (95% CI) | 3.7 (3 to 4.6) | 3.1 (2 to 4.8) | 4.4 (2.5 to 7.8) | 3.9 (2.5 to 6.2) | ---- | 2 (1.1-3.8) | ---- | 10.6 (6.2 to 18) | 1.6 (0 to 9-3) | 5.8 (2.4 to 14.1) |
Patients with prevaccination titer ≥40 (n;%) | 9(6%) | 5 (14%) | 2 (7%) | 1 (3%) | 0 | 0 | 0 | 0 | 1 (6%) | 0% |
Patients with postvaccination titer ≥40 (seroprotection) | 72(48%) | 15 (42%) | 15 (56%) | 14 (40%) | 0 | 2 (29%) | 1 (100%) | 8 (80%) | 7 (44%) | 10 (67%) |
Patients with positive immune response (seroconvers.) | 60( 40%) | 12 (33%) | 13 (48%) | 13 (37%) | 0 | 1 (14%) | 1 (100%) | 8 (80%) | 4 (25%) | 9 (60%) |
% immunized with seasonal influenza vaccine (2009/2010) | 51% | 64% | 56% | 43% | 50% | 43% | 100% | 50% | 56% | 27% |
18-60Â years | ||||||||||
Patients (number) | 142 | 14 | 11 | 18 | 3 | 3 | 1 | 31 | 35 | 26 |
GMT prevaccination mean (95% CI) | 10 (8.7 to 11.4) | 8.6 (5.5 to 13.5) | 10 (6 to 16.7) | 7.9 (5.7 to 11.1) | 40 (7.1 to 224) | 12.6 (1.7 to 92) | --- | 9.4 (7.1 to 12.4) | 9.8 (7.5 to 13) | 10.8 (7.5 to 16) |
GMT postvaccination mean (95% CI) | 58 (46.1 to 73) | 98 (40 to 235) | 66 (19 to 227) | 39 (17.7 to 84) | 64 (4.6 to 881) | 8 (1.1 to 58) | --- | 72 (47 to 110) | 51 (33 to 78) | 60 (35.7 to 100) |
Geometric mean fold increase (95% CI) | 5.8 (4.5 to 7.6) | 11.3 (4.4 to 29) | 6.6 (1.9 to 23.5) | 4.8 (2 to 11.6) | 1.6 (0.2 to 12) | 0.6 (0.1 to 4.6) | --- | 7.7 (4.5 to 13) | 5.2 (3 to 8.8) | 5.5 (3.2 to 9.5) |
Patients with prevaccination titer ≥40 (n;%) | 16 (11%) | 1 (7%) | 1 (9%) | 0 | 2(67%) | 0 | 1 (100%) | 3 (10%) | 3( 9%) | 5 (19%) |
Patients with postvaccination titer ≥40 (seroprotection) | 95 (67%) | 10 (71%) | 7 (64%) | 10 (56%) | 2 (67%) | 0 | 1 (100%) | 23 (74%) | 25 (71%) | 17 (65%) |
Patients with positive immune response (seroconvers.) | 86 (61%) | 9 (64%) | 7 (64%) | 10 (56%) | 1 (33%) | 0 | 1 (100%) | 23 (74%) | 20 (57%) | 15 (58%) |
% immunized with seasonal influenza vaccine (2009/2010) | 20% | 14% | 9% | 39% | 33% | 0 | 100% | 13% | 14% | 27% |